PTC Therapeutics, Inc. (PTCT)
Nasdaq · Healthcare · Biotechnology
$63.65+0.30%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $5.3B
- Forward P/E
- 23.8
- 52-week range
- $61.23 – $90.87
- 52-week change
- −2.07%
- EPS (trailing)
- −$0.65
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $1.7B (+114.52%)
- Net income
- $683M
- Operating margin
- 50.1%
- Diluted EPS
- $7.78
- Free cash flow
- $702M
From the company’s annual report on SEC EDGAR.
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd.
Headquarters: Warren, United States · 991 employees · ptcbio.com